Watch our recent interview with Yelena Janjigian (@YJanjigianMD) at #ASCO26 to hear about the emerging role of T-DXd in earlier settings for HER2+ upper #GICancers 🧬🩺💉

🔗:

#Oncology #ImmunoOnc #CaxTx @ASCO @MSKCancerCenter

The emerging role of T-DXd in earlier settings for upper gastrointestinal cancers

Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the evolving landscape of HER2-p...

ow.ly

How applicable are international #LungCancer screening guidelines to patients in Zimbabwe? 🫁🌍🩻

Find out from Tinashe Mazhindu, who shares insights into a retrospective study investigating this at #WCLC26 🔍

Watch:

#Oncology #LCSM @IASLC

Applicability of international lung cancer screening guidelines in Zimbabwe

Tinashe Mazhindu, MBChB, MMed, University of Zimbabwe, Harare, Zimbabwe, explores findings from a retrospective study ex...

ow.ly

At #ASCO26, Gil Shamai explores application of #AI models in predicting HER2 status and Oncotype DX scores in patients with #BreastCancer 🤖🧬🔬

Watch:

#Oncology #BCSM @ASCO

AI-based prediction of HER2 status and recurrence in breast cancer

Gil Shamai, PhD, Technion-Israel Institute of Technology, Haifa, Israel, discusses the application of artificial intellige...

ow.ly

How are BMI and prognosis associated in #NSCLC patients treated with TKIs? 🤔

Roberto Borea (@RobertoBoreaMD) explores findings from a pilot study investigating the association with us at #WCLC26 📊🫁

Watch:

#Oncology #LungCancer #LCSM @IASLC

Association between BMI and prognosis in NSCLC patients treated with TKIs

Roberto Borea, MD, The Ohio State University, Columbus, OH, discusses findings from a pilot study investigating the ...

ow.ly

What do the results of a pilot randomized trial suggest about short-term fasting compared with a free diet in patients with advanced high-grade serous #OvarianCancer receiving carboplatin + paclitaxel-based neoadjuvant #chemotherapy? 🍴💉🔍

Find out from Claudia Marchetti, who